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follow-up subclavian venogram performed six monthsLETTERS TO THE EDITOR
later revealed no stricture over the irradiated venous seg-
ment. However, a subclinical new venous stricture (ap-
proximately 45%) was noted at the junction of the stentPrevention of restenosis of
and the native subclavian vein. PTA successfully dilated
the stricture. A second course of brachytherapy at a dosecentral venous stricture after
of 12 Gy was similarly delivered to the new stricture site.
The patient had two more episodes of restenosis treatedpercutaneous transluminal by PTA in the nonirradiated venous segments 8 and 15
months later. Because of the concern of an overdoseangioplasty and endovascular of radiation, brachytherapy was not offered. The latest
venogram revealed no evidence of restenosis and 45%stenting by brachytherapy subclinical restenosis in the first and second irradiated
venous segment (20 and 15 months after brachytherapy),To the Editor: Here we report a 30-year-old chronic
respectively.hemodialysis patient who suffered from arteriovenous
Central venous stenosis is a well-recognized complica-fistula arm edema attributed to ipsilateral brachiocepha-
tion of subclavian vein cannulation for temporary hemo-lic vein stenosis. The stenosis was probably caused by
dialysis. PTA is the treatment of choice for these patientsprevious subclavian venous cannulation for temporary
who had poor surgical risk. Although the procedure-hemodialysis. In two years, she had recurrent episodes
related complication is low, it is associated with a highof venous restenosis that were treated with repeated per-
restenosis rate of up to 60% [1]. With the deploymentcutaneous transluminal angioplasty (PTA) using a 10 to
of a stainless steel stent, which limits the elastic recoil12 mm balloon catheter (Schneider, Bu¨lach, Switzerland)
of the vessel after PTA, the primary one-year patencyfour times, with three endovascular overlapping stents rate improves 60% to 70% [2]. The significant restenosis
implanted (20 mm, 5 cm, Gianturco stent; Cook, Bloom- rate even after vascular stenting is probably related to
ington, IN, USA; 14-mm, 10-cm Memotherm stent; Angio- intimal hyperplasia.
med, Karlsruhe, Germany; 10-mm, 3-cm Palmaz stent; Endovascular brachytherapy holds great promise in
Johnson & Johnson, Warren, New Jersey, USA). The the prevention of vascular restenosis as it focuses on
initial result of the PTA 6 stenting was satisfactory, with the root of the pathological process by inhibiting intimal
nearly full re-expansion of the stricture. However, there hyperplasia [3]. Local low-dose radiotherapy has been
were rapid restenoses of the stricture likely related to used for benign lesion-like keloid to limit fibrovascular
intimal hyperplasia. In an attempt to reduce the chance of proliferation after surgery, with no major long-term com-
restenosis, endovascular irradiation (brachytherapy) was plications encountered [4]. In a porcine model, gamma
offered. After a successful PTA and an implantation of a irradiation using 192Ir applied by an HDR remote after-
10 mm metallic stent, a 10-Fr guiding catheter was intro- loading technique was effective in inhibiting intimal hyper-
duced over a guide wire beyond the stenotic venous seg- plasia [5]. A radiation dose of 12 to 20 Gy appears to
ment. A 6-Fr blind-ended barrier catheter, with a dummy be effective in inhibiting intimal hyperplasia and restenosis
radio-opaque marker wire inside, was passed into the guid- [6]. Liermann et al reported that after a radiation dose
ing catheter. The barrier catheter prevented contact be- of 12 Gy delivered to the vessel wall by a HDR after-
tween the patient’s blood and the marker wire during the loader using 192Ir, there was a significant reduction of
restenosis of the femoropopliteal arteries for 7 to 60procedure. The patient was transferred to the oncology
months [7]. We applied the concept of employing brachy-radiation suite with the catheter in situ. After radiographic
therapy to prevent intimal hyperplasia in the arterialconfirmation of the proper position of the catheter, the
system to the venous system. Our preliminary experienceexact position of the stenosis was noted. The dummy
is encouraging. There was a substantial inhibition of re-marker wire was replaced by a flexible radiation applicat-
stenosis over the two irradiated venous segments duringing catheter [using iridium-192 (192Ir) as the gamma source]
the follow-up period (15 and 20 months after brachy-controlled by a high dose rate (HDR) remote afterloader
therapy).(microSelectron; Nucletron Engineering BV, Veenendaal,
Gamma irradiation has a longer range of radiationThe Netherlands). A single dose of 12 Gy was delivered
when compared with beta source. In the case of theat the luminal surface of the vessel wall over the stenotic
central vein, owing to its larger diameter, gamma irradia-segment with 10 mm proximal and distal margins. After
tion is probably a better choice. In addition, the presencethe procedure, the patient was put on heparin for 24
of metallic stent will not affect its dose distribution sig-hours, which was switched to aspirin subsequently. A
nificantly. Source centering is also less crucial in ensuring
circumferential dose homogeneity [8]. To protect medi-
Key words: brachytherapy, hemodialysis, stent, venous restenosis. cal personnel during handling, special room shielding in
a radiotherapy suite and a remote afterloading technique 1999 by the International Society of Nephrology
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time, and position can be controlled easily using a com-
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failure comparable to the findings in the study by DubachLong-term analgesic use and
and colleagues.
Asghar Rastegar and Michael Kashgarianrenal disease
Yale University
New Haven, Connecticut, USATo the Editor: In our recent review article [1] on page
316, we refer to the study by Dubach et al. [2] as the REFERENCES
only prospective study evaluating the relationship be-
1. Rastegar A, Kashgarian M: Clinical spectrum of tubulointerstitial
tween long-term analgesic use and renal disease. We nephritis. Kidney Int 54:313–347, 1998
2. Dubach UC, Rosner B, Pfister E: Epidemiologic study of abusewould like to acknowledge that a second prospective
of analgesics containing phenacetin: Renal morbidity and mortalitystudy involving 200 analgesic abusers and 200 controls
(1968–1979). N Engl J Med 308:357–362, 1983
followed for 7 years was carried out by Elseviers and 3. Elseviers MM, De Broe ME: A long-term prospective controlled
study of analgesic abuse in Belgium. Kidney Int 48:1912–1919, 1995De Broe [3]. This study found a risk ratio of 6.1 for renal
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